481 Phase 1/2 study of THOR-707 (SAR444245), a pegylated recombinant non-alpha IL-2, as monotherapy and in combination with pembrolizumab or cetuximab in patients (pts) with advanc... by Rui Wang, Judy Wang, Siqing Fu, Arun Azad, Gerald Falchook, Minal Barve, Hui Gan, Tarek Meniawy, Meredith McKean, Tira Tan, Giovanni Abbadessa, David Sommerhalder, Chen Chee, charlotte Lemeque, Nicole Acuff, Helene Pham, Jill Mooney, Neyssa Marina